This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Evans, M. Articles by Rees, A. Search for Related Content Social Bookmarking                         What's this?

Pharmacological management of hyperlipidaemia

University of Wales College of Medicine, Cardiff, marc.evans2{at}ntlworld.com

Aled Roberts

University Hospital of Wales, Cardiff

Alan Rees

University Hospital of Wales, Cardiff

Coronary heart disease (CHD) is a major cause of morbidity and mortality. Recent evidence supports the benefits of intensive low density lipoprotein-cholesterol (LDL-c) reduc-of intensive low density lipoprotein-cholesterol (LDL-c) reduction on CHD risk with various ongoing end point trials addressing the issue of optimal cholesterol reduction. Statins reduce LDL-c, and have been shown to reduce CHD event rates in both primary and secondary prevention trials. The magnitude of this effect is not fully accounted for by LDL-c reduction alone and may relate to effects on other lipid parameters.

Fibrates represent the best treatment for raising high density lipoprotein-cholesterol (HDL-c) and a variety of agents, which specifically target HDL-c, are under development.

New therapies being developed to meet the challenge of intensive cholesterol lowering include rosuvastatin, a potent statin, producing reductions in LDL-c of up to 69% and ezetimibe, a selective cholesterol absorption inhibitor, producing reductions in LDL-c of up to 25%.

This review summarises the evidence regarding dyslipidaemia and vascular risk and how advances in lipid-lowering therapy may be important in future management of hyperlipidaemia.

Key Words: cholesterol • coronary heart disease • statins.

References

• Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 1993;82:137-52.[Web of Science][Medline] [Order article via Infotrieve]
• Stamler J., Daviglus ML, Garside DB, Dyer AR, Greenland P., Neato JD Relationship between baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular and all cause mortality and longevity. JAMA 2000;284:311-18.[Abstract/Free Full Text]
• Ross R. The pathogenesis of atherogenesis: A perspective for the 1990s. Nature 1993;362:801-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Scandinavian Simvastatin Survival group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: A randomised placebo controlled trial. Heart Protection Study Collaborative group. Lancet 2002;360:7-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stamler J., Vaccaro O., Neaton JD, Wentworth D. for the Multiple Risk factor Intervention Trial Research group. Diabetes, other risk factors and 12year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:343-4.
• The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med 1998;338:1349-57.
• Genest JJ, McNamara JR, Ordovas JM et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol 1992;19:792-802.[Abstract]
• Assman G., Cullen P., Schulte H. The Munster Heart study (PROCAM): Results of follow up at 8 years. Eur Heart J 1998;19(suppl A):A2-A11.[Web of Science][Medline] [Order article via Infotrieve]
• Wilson PW, Anderson KM, Castelli WP Twelve year incidence of CHD in middle aged adults during the era of hypertensive therapy. The Framingham offspring study. Am J Med 1991;90:276-82.
• Expert panel on Detection Evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
• Wood D., De Backer G., Faegerman O. et al. Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-503.[Free Full Text]
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.[Abstract/Free Full Text]
• Gotto AM Jr, Whitney E., Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.[Abstract/Free Full Text]
• Sacks FM, Tonkin AM, Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.[Abstract/Free Full Text]
• Assmann G. Pro and Con: High-density lipoprotein, triglycerides and other lipid subfractions are the future of lipid management. Am J Cardiol 2001;87(suppl)2B-7B.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Vosper H., Khoudoli GA, Graham TL, Palmer CN Peroxisome proliferatoractivated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002;95(1):47-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Robins SJ, Collins D., Wittes JT et al. VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.[Abstract/Free Full Text]
• The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.[Abstract/Free Full Text]
• The DAIS study group. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lu W., Resnick HE, Jablonski KA et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study. Diabetes Care 2003;26(1):16-23.[Abstract/Free Full Text]
• Frost PH, Davis BR, Burlando AJ et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996;94:2381-8.[Abstract/Free Full Text]
• Cui Y., Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-19.reductase inhibitors on skeletal[Abstract/Free Full Text]
• Evans M., Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Safety 2002;25:649-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shek A., Ferrill MJ Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17.[Abstract]
• Thompson GR Executive summary of simvastatin. Journal of Drug Evaluation: Cardiovascular Medicine 2002;1:53-88.
• Miettinen TA, Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. BMJ 1998;316:1127-30.[Abstract/Free Full Text]
• Dujovne CA, Ettinger MP, McNeer JF et al. Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Davidson M., Ma P., Stein E. et al. Comparison of effects on low density lipoprotein cholesterol and high density lipoprotein cholesterol with rosuvastatin vs. atorvastatin in patients with type IIa or IIb hypercholesterolaemia. Am J Cardiol 2002;89:268-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hallikainen MA, Sarkkinen ES, Unsitupa MI Plant stanol esters affect serum cholesterol levels of hypercholesterolaemic men and women in a dose dependent manner. J Nutr 2000;130:767-76.[Abstract/Free Full Text]
• Catapano AL Ezetimibe: A selective inhibitor of cholesterol absorption. Eur Heart J 2001;3(suppl E)E6-E10.[CrossRef]
• Patrick JE, Kosoglou T., Stauber KL et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-7.[Abstract/Free Full Text]
• Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mori TA, Beilin LJ Long-chain omega-3-fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001;12:11-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Friedberg CE, Heine RJ, Janssen Mjfm, Grobbee DE Fish oil and glycemic control in diabetes - a meta-analysis. Diabetes Care 1998;21:494-500.[Abstract]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 3, 204-210 (2003)
DOI: 10.1177/14746514030030030901


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Evans, M. Articles by Rees, A. Search for Related Content Social Bookmarking                         What's this?